Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Klatskin Tumor 2Cholangiocarcinoma 2Sarcoma, Kaposi 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Epstein-Barr Virus Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3durvalumab 3derazantinib 3Folfox protocol 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2fludarabine 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide × Clear all
NCT03377179 2025-07-23

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

RedHill Biopharma Limited

Phase 2 Completed
65 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT03414489 2025-03-18

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

RedHill Biopharma Limited

No longer available
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡